48 citations
,
September 2013 in “Oncologist” This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
2 citations
,
March 2021 in “Cutis” This article highlights that permanent chemotherapy-induced alopecia can occur and is more commonly associated with taxane therapy, advising awareness among patients and clinicians.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.
August 2026 in “Cosmoderma” This review identifies sebaceous gland disorders as key indicators of hormonal imbalances, detailing how various hormones affect sebaceous function, and emphasizes a multidisciplinary approach to improve diagnosis and management by integrating endocrine, metabolic, and dermatologic insights.